| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 10/03/2006 | US7115625 Administering mixtures of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, and analogues, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, vasodilators and diuretics, for prophylaxis of congestive heart failure |
| 10/03/2006 | US7115623 1,8-Naphthyridin-2(1H)-one derivatives; antiasthmatic, antihistamine, and bronchodilator agents; nontoxic, side effect reduction |
| 10/03/2006 | US7115617 Anticarcinogenic and kinase inhibitor; a heteroaryl(containing atleast one oxygen or sulfur atom)amino substituted pyrimidine compound |
| 10/03/2006 | US7115616 Pyrimidinone compounds |
| 10/03/2006 | US7115613 Compound of fused nitrogen containing heterocyclic ring, useful for treating prostate and angiogenic disorders |
| 10/03/2006 | US7115607 Substituted piperazinyl amides and methods of use |
| 10/03/2006 | US7115599 Guanylate cyclase stimulant; cardiovascular disorders; thrombosis; antiischemic agents; sexual disorders; antiinflammatory agents; central nervous system disorders |
| 10/03/2006 | US7115597 Tyrosine kinase inhibitors |
| 10/03/2006 | US7115588 Applying semi-crystalline acetylglucosamine polysaccharide for treating vasoconstriction, reduction in blood flow |
| 10/03/2006 | US7115573 Prodrug compounds with an isoleucine |
| 10/03/2006 | US7115565 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 10/03/2006 | US7115559 Administering factor XIII to patients afflicted with bleeding due to a coumarin anticoagulant-induced vitamin K deficiency |
| 10/03/2006 | US7115554 Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| 10/03/2006 | US7115405 Recombinantly produced, enzymatically active, includes two amino acid motifs |
| 10/03/2006 | US7115395 DNAs encoding guinea pig histamine receptors of the H4 subtype |
| 10/03/2006 | US7115394 Isolated and/or recombinantly produced polypeptide; use in regulating spermatogenesis, cell differentiation and proliferation |
| 10/03/2006 | US7115392 Polynucleotides encoding human vascular endothelial growth factor 2 |
| 10/03/2006 | US7115380 Applications of peptides derived from the cytoplasmic domain of amyloid precursor protein (APP) |
| 10/03/2006 | US7115372 Detection of modulators of gene transcription inhibition; obtain sample of cells, incubate with modulator, monitor transcription pattern, compare to control, evaluate for transcription inhibition |
| 10/03/2006 | US7115279 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 10/03/2006 | US7115268 Peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, which may be polymeric, that provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections |
| 10/03/2006 | US7115267 polypeptide comprising hemoglobin alpha chain wherein the C-terminal hydrophobic domain has been substituted or deleted; regulating stem cell cycle and accelerating the post-chemotherapy peripheral blood cell recovery; inhibitors and stimulators of stem cell proliferation. |
| 10/03/2006 | US7115260 Interleukin-1β converting enzyme like apoptotic protease-6 |
| 10/03/2006 | US7115250 Heating erectile dysfunction drug to vaporize; cooling to form condensation aerosol; drug delivery |
| 10/03/2006 | CA2288046C Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| 10/03/2006 | CA2279535C Dermatan disulfate, an inhibitor of thrombin generation and complement activation |
| 10/03/2006 | CA2249654C Benzoxazines for enhancing synaptic response |
| 10/03/2006 | CA2247946C Anticachectic composition |
| 10/03/2006 | CA2215319C Compositions comprising nicotinylalanine and an inhibitor of glycine conjugation or vitamin b6 |
| 10/03/2006 | CA2189221C Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them |
| 09/28/2006 | WO2006101205A1 Method for activation of t cells and kit for production of activated t cells |
| 09/28/2006 | WO2006101163A1 Medicinal composition for treating/preventing motor organ disease |
| 09/28/2006 | WO2006101108A1 Novel cyclic aminophenylalkanoic acid derivative |
| 09/28/2006 | WO2006101105A1 Agent for treatment of psoriasis |
| 09/28/2006 | WO2006101104A1 Agent for treatment of arthritis |
| 09/28/2006 | WO2006101103A1 Agent for treatment of hematopoietic tumor |
| 09/28/2006 | WO2006101102A1 Agent for treatment of solid tumor |
| 09/28/2006 | WO2006101052A1 Novel acetylene derivative |
| 09/28/2006 | WO2006101000A1 Anti-dermatan sulfate antibody and functional sulfated oligosaccharide |
| 09/28/2006 | WO2006100922A1 Cinnamoyl compound and use thereof |
| 09/28/2006 | WO2006100468A1 Treatment of laminitis |
| 09/28/2006 | WO2006100208A1 1-benzylindole-2-carboxamide derivatives |
| 09/28/2006 | WO2006073333A3 Magnetoresonance preparations, device for individually selecting said preparations for increasing an organism life activity in actual environmental conditions |
| 09/28/2006 | WO2005080384A3 Benzimidazole derivative and use as aii receptor antagonist |
| 09/28/2006 | WO2005064008A9 Method and compositions for identifying anti-hiv therapeutic compounds |
| 09/28/2006 | WO2005021776A3 METHODS OF USING MAMMALIAN RNase H AND COMPOSITIONS THEREOF |
| 09/28/2006 | WO2002008267A9 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/28/2006 | US20060217557 Polymorphic form XVI of fexofenadine hydrochloride |
| 09/28/2006 | US20060217546 3-Deoxypentopyranosyl nucleic acid, its production and its use |
| 09/28/2006 | US20060217536 Monoclonal antibody that has an extremely high binding ability to human ZAQL-1 and can neutralize or inhibit its activity, useful for diagnosing, preventing and treating endometrial cancer, endometriosis or ovulation disorders. |
| 09/28/2006 | US20060217530 Active against C5a receptors on polymorphonuclear leukocytes and macrophages; peptidomimetics; for treatment of inflammation |
| 09/28/2006 | US20060217439 Compounds with stabilized S-nitrosyl group and a free alcohol or a free thiol; nitric oxide (NO) releasing; bacteristats; reacting a polythiol or a thioalcohol with a nitrosylating agent (S-Nitrosyl-N-acetyl-D,L-penicillamine (SNAP) and and tert-butylnitrite); |
| 09/28/2006 | US20060217429 Treating stroke or reccurence with an ACE inhibitor selected from quinapril, captropril, lisinopril, perindopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, delapril, moveltipril and trandolapril |
| 09/28/2006 | US20060217424 Compounds for the inhibition of nitric oxide synthase |
| 09/28/2006 | US20060217418 Antagonists for melanin concentrating hormone-1 receptors; antidepressants, anxiolytic agents; incontinence, obesity |
| 09/28/2006 | US20060217413 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor |
| 09/28/2006 | US20060217407 Compositions and Formulations of 9-Nitrocamptothecin Polymorphs and Methods of Use Therefor |
| 09/28/2006 | US20060217406 7-(3-Pyridyl)-1,7-diazaspiro-[4,4]nonane and its salts and proline amides; capable of affecting nicotinic cholinergic receptors, e.g., as modulators of specific nicotinic receptor subtypes; neuroprotective agents |
| 09/28/2006 | US20060217388 Phthalazine derivatives for treating inflammatory diseases |
| 09/28/2006 | US20060217384 e.g. 1-((3-Phenyl-1,2,4-triazolo(3,4-a)phthalazines-6-yl)carbonyl)piperidine; high affinity to the benzodiazepine site of GABAA receptors; central nervous system (CNS) diseases such as depression, anxiety, and attention deficit disorder |
| 09/28/2006 | US20060217373 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same |
| 09/28/2006 | US20060217364 Beta-lactamyl vasopressin V1a antagonists |
| 09/28/2006 | US20060217361 Bicyclic 6-alkylidene-penems as beta-lactamase inhibitors |
| 09/28/2006 | US20060217353 24-sulfoximine vitamin D3 compounds |
| 09/28/2006 | US20060217349 Having antiinflammatory, anti-pyretic and anti-diarrheal properties |
| 09/28/2006 | US20060217348 Pyrazolo[1,5-a] pyridines and medicines containing the same |
| 09/28/2006 | US20060217339 Breast cancer, prostate cancer, brain cancer, head and neck cancer, myeloma, melanoma, leukemia and lymphoma; promotion of apoptosis; may have phosphorothioate, 2'-O-(2-methoxyethyl) sugar, and/or 5-methyl cytosine modifications; useful prophylactically, and as clinical research and diagnostic tools. |
| 09/28/2006 | US20060216808 Isolated, recombinantly produced, enzymatically active hyaluronan synthase; a single protein that is a dual-action catalyst that utilizes UDP-GlcA and UDP-GlcNAc to synthesize hyaluronic acid |
| 09/28/2006 | US20060216794 Hyaluronan synthase gene and uses thereof |
| 09/28/2006 | US20060216793 Culturing Bacillus strain with purified nucleic acid segment having coding region encoding enzymatically active hyaluronan synthase to produce hyaluronic acid; genetic engineering |
| 09/28/2006 | US20060216788 CASH (CASPASE HOMOLOGUE) with death effector domain, modulators of the function of FAS |
| 09/28/2006 | US20060216777 Immobilization on solid support |
| 09/28/2006 | US20060216758 Antibodies to transferrin receptor-like proteins |
| 09/28/2006 | US20060216745 Polynucleotides, expression vectors, and host cells for culturing truncated tryptophanyl-tRNA synthetase polypeptides having chemokine activity; bioassay; drug screening; antitumor agents, antimetastasis agents |
| 09/28/2006 | US20060216317 Delivery of polynucleotide agents to the central nervous system |
| 09/28/2006 | US20060216245 Composition for local anesthesia |
| 09/28/2006 | US20060216244 Delivery of compounds for the treatment of parkinson's through an inhalation route |
| 09/28/2006 | US20060216243 Delivery of Beta-Blockers Through An Inhalation Route |
| 09/28/2006 | US20060216241 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant; anxiety, muscle spasms |
| 09/28/2006 | DE19903876B4 Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten A method for in vitro generation and accumulation of interleukin-1 receptor antagonist |
| 09/28/2006 | CA2602559A1 Agent for treatment of hematopoietic tumor |
| 09/28/2006 | CA2602397A1 Therapeutic agent for solid tumor |
| 09/28/2006 | CA2600074A1 Novel cyclic aminophenylalkanoic acid derivative |
| 09/28/2006 | CA2599855A1 1-benzylindole-2-carboxamide derivatives |
| 09/28/2006 | CA2599794A1 Cinnamoyl compound and use thereof |
| 09/27/2006 | EP1705169A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 09/27/2006 | EP1704865A2 Treatment of C. difficile toxin B associated conditions |
| 09/27/2006 | EP1704864A2 Process for producing an injectable pharmaceutical preparation |
| 09/27/2006 | EP1704863A2 Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent |
| 09/27/2006 | EP1704861A1 Lipase inhibitor |
| 09/27/2006 | EP1704857A1 Abca1 stabilizer |
| 09/27/2006 | EP1704855A2 2-Cyclopenten-1-one and its Derivatives as Inhibitors of the NF-kappa B Factor |
| 09/27/2006 | EP1534687B1 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators |
| 09/27/2006 | EP1501826B1 Substituted indoles as alpha-1 agonists |
| 09/27/2006 | EP1486208B1 Use of a novel preventive for infections |
| 09/27/2006 | EP1461062B1 Composition and method for treating chronic allograft rejection |
| 09/27/2006 | EP1458716B1 Bicyclic n-arylamides |
| 09/27/2006 | EP1421078B1 Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| 09/27/2006 | EP1404341B1 Active substance combination for medicamentous therapy of nicotine dependency |
| 09/27/2006 | EP1395590B1 Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists |